Company: AEMD
Filing Date: 2025-06-26
Form Type: 10-K
Source: 0001683168-25-004780
Chunk: 665

Company: AETHLON MEDICAL INC
Filing Date: 2025-06-26
Form: 10-K
Item: Item 3
Chunk 665
---
 selecting director candidates or recommending such candidates to our Board of Directors for selection; and

    ·
    reviewing and evaluating the performance of our Board of Directors.

 65 

The
Nominating and Corporate Governance Committee has adopted a charter, which can be found on our website at “Investors – Governance
– Governance Documents.” The reference to or inclusion of our website address in this Amendment No. 1 does not include or
incorporate by reference the information on our website into this Amendment No. 1.

Stockholder Nominees for Director

There
have been no material changes to the procedures by which stockholders may recommend nominees to the Board of Directors.

Code of Ethics

In February 2005, our Board
of Directors approved a “Code of Business Conduct and Ethics” (as amended from time to time, the “Code”), which
applies to our principal executive officer, our principal financial officer, our principal accounting officer and persons performing similar
tasks. In February 2020, the Board of Directors adopted an amended Code, which is applicable to all of our directors, officers and other
employees and which is available on our website at www.aethlonmedical.com. If we make any substantive amendments to, or grant any waivers
from, the Code for any officer or director, we will disclose the nature of such amendment or waiver on our website or in a Current Report
on Form 8-K. The inclusion of our website address in this Amendment No. 1 does not include or incorporate by reference the information
on our website into this Amendment No. 1.

Incentive Compensation Recoupment Policy

We
have adopted an incentive compensation recovery policy (the “Compensation Recovery Policy”) that is designed to comply with,
and will be interpreted in a manner consistent with, Section 10D and Rule 10D-1 of the Exchange Act and the applicable rules of the Nasdaq
Stock Market, including any interpretive guidance provided by Nasdaq. Under our Compensation Recovery Policy, in the event of an accounting
restatement due to the Company’s material noncompliance with any financial reporting requirement under the securities laws, including
any required accounting restatement to correct a material error in previously issued financial statements, or that would result in a material
misstatement if the error were corrected in the current period or left uncorrected in the current period, the Company must recover erroneously
awarded incentive-based compensation previously paid to the Company’s executive officers in accordance with the